X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA FRESENIUS KABI ONCO. NATCO PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 13.3 22.1 60.0% View Chart
P/BV x 3.8 3.1 121.9% View Chart
Dividend Yield % 1.2 0.0 -  

Financials

 NATCO PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
FRESENIUS KABI ONCO.
Mar-13
NATCO PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,080176 613.6%   
Low Rs67179 855.2%   
Sales per share (Unadj.) Rs592.137.7 1,571.1%  
Earnings per share (Unadj.) Rs188.45.1 3,699.1%  
Cash flow per share (Unadj.) Rs206.36.7 3,069.1%  
Dividends per share (Unadj.) Rs8.250-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs833.642.5 1,959.4%  
Shares outstanding (eoy) m36.90158.23 23.3%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.53.4 43.8%   
Avg P/E ratio x4.625.0 18.6%  
P/CF ratio (eoy) x4.218.9 22.4%  
Price / Book Value ratio x1.13.0 35.1%  
Dividend payout %4.40-   
Avg Mkt Cap Rs m32,31120,135 160.5%   
No. of employees `0004.81.2 419.4%   
Total wages/salary Rs m3,256703 463.0%   
Avg. sales/employee Rs Th4,522.55,176.2 87.4%   
Avg. wages/employee Rs Th674.0610.4 110.4%   
Avg. net profit/employee Rs Th1,439.0699.6 205.7%   
INCOME DATA
Net Sales Rs m21,8485,963 366.4%  
Other income Rs m40418 2,244.4%   
Total revenues Rs m22,2525,981 372.0%   
Gross profit Rs m9,2841,430 649.2%  
Depreciation Rs m662258 256.7%   
Interest Rs m154-26 -592.3%   
Profit before tax Rs m8,8721,216 729.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,920342 561.1%   
Profit after tax Rs m6,952806 862.6%  
Gross profit margin %42.524.0 177.2%  
Effective tax rate %21.628.1 76.9%   
Net profit margin %31.813.5 235.4%  
BALANCE SHEET DATA
Current assets Rs m21,3075,102 417.7%   
Current liabilities Rs m5,9202,385 248.2%   
Net working cap to sales %70.445.6 154.6%  
Current ratio x3.62.1 168.3%  
Inventory Days Days73150 48.8%  
Debtors Days Days107113 94.0%  
Net fixed assets Rs m14,9865,148 291.1%   
Share capital Rs m369158 233.2%   
"Free" reserves Rs m30,3536,556 463.0%   
Net worth Rs m30,7606,732 456.9%   
Long term debt Rs m0952 0.0%   
Total assets Rs m37,15110,388 357.6%  
Interest coverage x58.6-45.8 -128.0%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.60.6 102.4%   
Return on assets %19.17.5 254.8%  
Return on equity %22.612.0 188.8%  
Return on capital %29.314.6 200.9%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m10,3225,298 194.8%   
Fx outflow Rs m2,9781,772 168.1%   
Net fx Rs m7,3433,525 208.3%   
CASH FLOW
From Operations Rs m4,6361,274 363.9%  
From Investments Rs m-11,155-1,204 926.3%  
From Financial Activity Rs m6,509-196 -3,319.2%  
Net Cashflow Rs m-18-126 14.3%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 81.0 1.8%  
Indian inst/Mut Fund % 7.8 0.3 2,613.3%  
FIIs % 16.6 9.6 173.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 9.1 285.7%  
Shareholders   25,395 42,599 59.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   AUROBINDO PHARMA  MERCK LTD  NOVARTIS  FULFORD INDIA  ORCHID PHARMA LTD  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 307 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended on a strong note. Gains were seen in the metal sector.

Related Views on News

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Dec 17, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - NOVARTIS COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS